Cell line Development & Engineering Asia Conference

0 %
100 %
Information about Cell line Development & Engineering Asia Conference
Science

Published on April 24, 2014

Author: LeiChingYew

Source: slideshare.net

Description

The 3rd Annual Cell Line Development & Engineering Asia conference brings together experts and top scientists from pharma/biotech companies, CMOs, leading technology providers and research institutes to discuss current opportunities and challenges, such as quality and titer improvements, best cell culture media design, development and banking, overcoming regulatory hurdles and more.

www.celllineasia.com Produced by: Associate Sponsor: Session Spotlight Sponsors: Exhibitors: Associations: REGISTER NOW! Customer Service Hotline: +65 6508 2401 / +86 21 2326 3680 International Marketing Partner: Media Partners: 20 — 23 May 2014 Grand Hyatt Shanghai, China Accelerating Your Cell Line Development with Efficacy & Quality THE 2014 NEW EXPERT FACULTY INCLUDES: Dr Zhao (David) Xiao Jian Senior Vice President & ChiefTechnologyOfficer, Wuhan YZY Biopharma, China Dr H. Fai Poon Director, Cell Culture, Hisun Pharmaceuticals, China Dr Chengbin Wu Chief Scientific Officer & President of R&D, Shanghai CP Guojian Pharmaceutical, China Dr Qian Xue Ming CEO & Chairman, Mabspace Biosciences, China What’s New for 2014? New & Unpublished Data on Targeted Integration, Glycosylation, Transient Expression & Clone Selection Cell Line Development Strategies for Complex Biologics Achieve an Ideal Cell Culture Media for High Yield & Reproducibility Navigate the Cell Line Regulatory Landscape for Your Drug Innovative Technology Showcase to Accelerate your Cell Line Development Process Pre-Conference Workshops: 20 May 2014 Optimizing Cell Culture Media Development & Design Strategies Cell Banking Management Post-Conference Workshop: 23 May 2014 The Road to Commercialization: From Cell to MarketC B A BIOBIO MANUFACTURING BIOSIMILARSSIMILARSSIMILARSBIBI ASIA BI Co-located with: Part of Bronze Sponsor: PRODUCTION BIOPHARMA DEVELOPMENT & WEEK C LL LINEC LL LINEC LL LINE DEVELOPMENT & ENGINEERING ASIA 3RD ANNUAL Life Sciences

REGISTERTODAY! +6565082401/+862123263680 register@ibcasia.com.sg www.celllineasia.com C LL LINEC LL LINEC LL LINE DEVELOPMENT & ENGINEERING ASIA CONFERENCE DAY ONE 21 MAY 2014 | WEDWEDNESDAY 8:00 Morning Coffee and Registration Opens 8:50 Welcome Address from IBC Asia & Ice Breaker Exchange Business Cards & Get To Know Industry Peers 9:00 Chairperson’s Opening Remarks BIOPHARMA VISIONARY KEYNOTE SESSIONS 9:05 Global Biopharma Outlook • Trends in the global biopharma industry • Priorities of investment in China and opportunities for growth • Challenges and opportunities in the Asian region • The role of Biosimilars in the region’s biopharma industry • Key criteria to further the development of the sector in China and Asia Panelists: Scott Liu, CEO, Henlius Pharmacueticals, China Youling Wu, CEO, Zhejiang Teruisi, China Jianguo Yang, Principal Scientist, Sanofi Genzyme, USA Jeremy Caudill, Global VP Business Development, Samsung Biologics, Korea Abdullah Baaj, CEO, Boston Oncology, USA Sameer Agarwal, SeniorVicePresident,BusinessCenterStrategic Marketing, Business Unit Generic Drugs & Standard Solutions, Fresenius Kabi Deutschland GmbH, Germany 9:50 Biopharma Regulatory Updates & Development • Clinical approvals for biopharmaceuticals • Regulatory differences between the FDA/EMA/ICH and local agencies in China and other emerging markets such as India and SEA. • How to demonstrate process consistency and what is required • Accelerating IND applications • Updates on Biosimilars guidelines in key Asian markets Panelists: Dr Victoria Elegant, Vice President of Medical & Regulatory Affairs, Baxter, China Prof. Andrea Laslop, Head of Scientific Office, Austrian Agency for Food and Health Safety, Austrian Member, European Medicines Agency, Austria BIOPHARMA TECHNOLOGY SHOWCASE 10:30 Cutting Edge Solutions & Innovation in Biopharma If you have leading edge technology and solutions and would like to showcase your innovation in front of biopharma industry stakeholders, please contact Yvonne Leong: Yvonne.leong@ibcasia.com.sg 11:00 Morning Networking & Refreshment Break 11:45 Chairperson’s Opening Remarks Dr Jianguo Yang, Principal Scientist, Genzyme/Sanofi, USA ENSURING QUALITY AND STABILITY IN CELL LINE DEVELOPMENT 11:50 Applying Quality by Design (QbD) to Cell Culture Development • How to develop a Quality by Design (QbD) strategy in cell line development • How to implement QbD in cell line development • What are the Critical Quality Attributes (CQA) in upstream processing impact on downstream processing • What are the CQA requirements on protein glycosylation • How quality defines the process Dr Jianguo Yang, Principal Scientist, Genzyme/Sanofi, USA 12:20 Molecular Profiling of Recombinant Protein Quality Quantity and Quality, both are critical criteria for the success of recombinant protein expression in cell line development.Whilst some quality attributes directly determine protein structure and, hence, function, others can lead to events that have secondary (and potentially deleterious)effectsto therapeuticefficacy,suchasstability, aggregation and immunogenicity. I will review profiling technologies (in current and potential future use) that assess quality of recombinant proteins and discuss how information and interpretation of 'omics approaches may be applied to direct/improve/engineer structural quality of specific products. Prof. Alan Dickson, Professor of Biotechnology, Director, Centre of Excellence in Biopharmaceuticals, The University of Manchester, UK REGULATORYLEADERSPANEL * Conference Proceedings will be conducted in English. 12:50 Networking Lunch & VIP Tables VIP Table 1 Dr Liu Xiaolin, Vice President of Process Development, Innovent Biologics, China VIP Table 2 Dr Ting Xu, CEO, AlphaMab, China If you would like to be seated on a table with the above guests in an exclusive lunch setting, please register your interest with weifang.sim@ibcasia.com.sg. Limited seats are available! 2:30 Control of r-Protein Quality Attributes by Cell Line Engineering and Media Design Dr. Nan Lin, Principal Scientist, CHOZN Platform, SAFC, USA IMPROVING GENE TRANSFECTION 3:00 Targeted Integration of “Hotspots” in CHO Genome for Rapid Generation of Stable & High Monoclonal Antibody Producing Cell Lines We have developed a FRT/FLP based cassette exchange strategy for efficient targeting of monoclonal antibody (mAb) genes into predetermined hotspots in the CHO genome. Clones were first generated by random integration of an optimized tagging vector containing FRT sequences, a GFP reporter gene, and a stringent selection marker. Subsequent FACS screening of gene expression level, stability, and cassette exchange efficiency identified the suitable master clones with tagged hotspots. The targeting vector was designed to express the mAb light chain and heavy chain at balanced ratios and optimized for enhancing the selection stringency of correct cassette exchange. We have generated master clones which allow generation of stable and high monoclonal antibody producing cell lines in less than two months. DrYuanshengYang , Research Scientist, Animal Cell Technology, Bioprocessing Technology Institute, A*Star, Singapore 3:30 Afternoon Networking & Refreshment Break 4:00 Optimization ofTransient Gene Expression in HEK293 Cells Polyethylenimine (PEI) mediated transient gene expression has become a commonly used method for the fast preparation of recombinant proteins at different scales.The sizes and binding strength between PEI and DNA molecules are considered the key qualities of PEI/DNA complexes to accomplish the consecutive events from their cellular intake to nuclear gene transcription. In electrolytic aqueous media, the association between PEI and DNA is dynamic and reversible, which may have a profound impact on process design and medium optimization. This presentation will discuss the various approaches in increasing the binding affinity between PEI and DNA and methods in overcoming the various challenges faced in optimizing PEI mediated transient gene expression would be discussed Prof. Bing Q. Shen, Professor, College of Pharmacy, Nankai University, China INNOVATIVE TECHNOLOGIES FOR CELL LINE DEVELOPMENT 4:30 Ambr & Ambr250: Systems Enabling High Throughput Biologics Development • Introducing the new ambr250 platform • Novel applications for ambr and ambr250 in consistently predicting culture behavior at a larger scale • Overcoming diverse process challenges in eukaryotic or prokaryotic platforms using the ambr and ambr250 platforms Ian Ransome, Director, Asia Pacific, TAP Biosystems, UK 5:00 Development of an Automated & Disposable Perfusion Platform • Combining two disposable technologies: the CELL-tainer and the acoustic CytoPerf perfusion system • Cost effective and automated process control to manage perfusion • Addressing industrial concerns for perfusion Gael Peron, Global Director of Sales and Marketing, Charter Medical, USA 5:30 Chairperson’s Summary of Day One 5:40 Speed Networking & Networking Cocktail VIP 1 Dr Junhua Qiao, AssociateDirector, Wuxi Apptec, China VIP 2 Dr Xueming Qian, CEO, Mabspace Biosciences, China Exclusive to Registered Participants Only: Limited Spots Available! Participants have the chance to spend two minutes getting to know the below key experts in the Biopharma industry! Secure your place today with weifang.sim@ibcasia.com.sg 7:00 End of Conference Day One UNPUBLISHEDDATAUNPUBLISHEDDATA

C LL LINEC LL LINEC LL LINE DEVELOPMENT & ENGINEERING ASIA CONFERENCE DAY TWO 22 MAY 2014 | THURSTHURSDAY REGISTERTODAY! +6565082401/+862123263680 register@ibcasia.com.sg www.celllineasia.com 8:55 Chairperson’s Opening Remarks Dr Wei Kuang Chi, Vice President, Development Centre for Biotechnology, Taiwan OPTIMIZING & MODIFYING THE GLYCOSYLATION PROCESS 9:00 Industry Best Practices on Glycosylation Site Control • Process control strategies for glycosylation site control • Optimization and prediction of glycosylation site Sanjeev Gupta, Deputy General Manager – Biosimilars Development, IPCA Laboratories, India 9:30 CHO Glycosylation Mutants as Potential Hosts to Produce Therapeutic Antibodies Proper and consistent glycosylation has long been a major challenge for the biotech industry. We have generated a panel of VHO glycosylation mutants from the CHO-K1 cell that can be used to produce recombinant antibodies with consistent yet unique glycan structures.These cells can be easily cultured in serum-free media with growth rates with final cell densities comparable to that of wild type CHO-K1 cells making them ideal to be used in the biopharmaceutical industry Dr Zhi Wei Song, Principal Scientist, Expression Engineering, Bioprocessing Technology Institute, A*Star, Singapore 10:00 Morning Networking & Refreshment Break ADVANCES IN CLONE SCREENING/SELECTION 10:30 ReducingTimelines for Generating Recombinant Cell Lines through Clone Screening & Selection • Cell line development strategies and protein expression platforms • Vector design for gene expression and protein production in CHO cells • Methods for streamline selection and clonal isolation • Timeline for cell line development Dr Noelle-Ann Sunstrom, CEO, Neuclone, Australia 11:00 Accelerating Antibody Process Development: Exploring the Synergies Between the Use of Engineered Host Cells and Process Development James Rance, HeadofDevelopmentServices, LONZA Biologics, Singapore COMMERCIALIZING CELL LINES 11:30 From Lab to Commercial Development: Improving the Manufacturability & Scalability of Mammalian Cell Lines • What are the key factors that have to be taken into consideration in scaling up cell lines • Improving the productivity in a scale up process • Overcoming the various scale up challenges David Hughes, CEO, BioPharmaceuticals Australia, Australia 12:00 Networking Luncheon & VIP Lunch Tables VIP Table 1 Dr H.Fai Poon, Director, Cell Culture, Hisun Pharmaceuticals, China VIP Table 2 Dr Zhao (David) Xiao Jian, Senior Vice President & Chief Technology Officer, Wuhan YZY Biopharma, China If you would like to be seated on a table with the above guests in an exclusive lunch setting, please register your interest with weifang.sim@ibcasia.com.sg. Limited seats are available! CELL CULTURE MEDIA DEVELOPMENT 1:30 Do We Need Chemically Defined Media? • Do we need CD media and process? • Benefits and disadvantages of developing CD media • WhatisrequiredtodevelopCDmediaandupstreammanufacturing process Dr Shun Luo, President, JS Biosciences, China 2:00 Approaches in Developing Chemically Defined Media • Identification and optimization of key components • Case studies on using chemically defined medium to grow cells of high productivity • Challenges in developing chemically defined medium and how to overcome them Dr Chengbin Wu, Chief Scientific Officer & President of R&D, Shanghai CP Guojian Pharmaceutical, China STRATEGIES IN DEVELOPING COMPLEX BIOPRODUCTS 2:30 mAb Cell Line Development Strategies for Biosimilars • Landscape of mAb biosimilar • How to define the target mAb molecule for making biosimilars • Bridging strategies • Biosimilars: How similar is similar? • Key consideration for cell line/cell culture development: Similarity, Stability, Reproducibility and Productivity Dr. Joe X. Zhou, CEO, Genor BioPharma, China 3:00 Afternoon Networking & Refreshment Break 3:30 Advancements in Developing Complex Biologics from Mammalian Cell Lines Complex biologics such as ADCs and bispecifics are an exciting class of drugs that holds huge potential for the future of therapeutics. This presentation will discuss the various recent research advancements that were made in developing various innovative complex biologics from cell lines, the challenges faced and how were they addressed. Prof. Peter Gray, Director, Australian Institute of Biotechnology & Nanotechnology (AIBN), Australia 4:00 Mammalian vs Non-Mammalian Cell Line Development Platforms • Challenges and benefits in developing bioproducts from various cell line development platforms • Comparison of safety, cost and quality of non-mammalian cell lines and mammalian cell lines • Future trends in moving away from CHO cell lines Moderator: Dr Jianguo Yang, Principal Scientist, Genzyme/Sanofi, USA Panelists: Dr Wei Kuang Chi, Vice President, Development Centre for Biotechnology, Taiwan Dr H.Fai Poon, Director, Cell Culture, Hisun Pharmaceuticals, China Dr Ting Xu, CEO, AlphaMab, China ROUND TABLE DISCUSSIONS 4:40 Round Table Discussions 1. New Cell Culture Platform Technology for Biosimilar and Biobetter Dr H.Fai Poon, Director, Cell Culture, Hisun Pharmaceuticals, China 2. ADC, Multispecifc and Fc Modification, How Does Cell Culture Help? Dr Zhao (David) Xiao Jian, SVP & CTO, Wuhan YZY Biopharm, China 3. Selection and Stability Research on Cell Lline Prof. Peter Gray, Director, Australian Institute of Biotechnology & Nanotechnology (AIBN), Australia 4. Clone Selection Platforms and Future possibilities Dr Junhua Qiao, Associate Director, Wuxi Apptec, China Limited Seats Are Available! Secure your place with weifang.sim@ibcasia.com.sg 5:30 Chairperson’s Summary of the Day & End of Conference UNPUBLISHEDDATA PANELDISCUSSION UNPUBLISHEDDATA

C LL LINEC LL LINEC LL LINE DEVELOPMENT & ENGINEERING ASIA WORKSHOPS REGISTERTODAY! +6565082401/+862123263680 register@ibcasia.com.sg www.celllineasia.com Pre-Conference Workshop A: 20 May 2014 (0900-1230) Optimizing Cell Culture Media Development & Design Strategies About Your Workshop Leader: Dr Zhao (David) Xiao Jian, Senior Vice President & Chief Technology Officer, Wuhan YZY Biopharma, China Dr Zhao completed his doctorate in Biochemistry at Colorado State University in 1994. After his post-doctoral researches at University of Colorado and the Southeast Blood Research Institute atWisconsin, he joined Amersham Pharmacia in 1998 as a scientist working on microarray technologies. He worked as the group leader and Sr. scientist at Orchid Bioscience, the director of development at US genomics, R&D director at Invitrogen, and the director of cell culture at EMD Millipore-a division of Merck A/G, CSO and board member of Yison bioscience. As CTO and Sr. VP of YZY biopharma at Wuhan, he is currently responsible for antibody therapeutic development and manufacturing. Dr. Zhao has developed many technologies and products during his career. Cell Banking Management Maintaining a cell bank to preserve these cell lines is no simple task. Various factors have to be taken into consideration and maintained such as quality, safety, stability, productivity, preservation as well as ensuring that the cell bank is free from contamination. This workshop aims to introduce the various aspects of cell banking. Sanjeev Gupta has a Masters in Applied Microbiology & Biotechnology and is pursuing his Ph.D. in Microbial biotechnology. He has over 13 years of industrial experience and has been working in development of recombinant therapeutic proteins & monoclonal antibodies (Biosimilars). So far, he developed and delivered over 10 recombinant clones of which three Biosimilar products has been launched already in the Indian market and the rest is in developmental or clinical phase, and expected to be launched soon. He also has experience in developing the human antibody gene library in unique and novel expression platform. During his professional tenure, he worked at various positions in reputed Indian biopharmaceuticals industries such as Zydus Cadila, Wockhardt Research, Panacea Biotech, Intas Biopharmaceuticals. Cell culture media plays a huge role in the success of cell development. Being able to develop a high-quality media which is able to give reproducible results and high yields can contribute significantly to the cost, scalability, process robustness as well as the time to market. This workshop will provide attendees a strong foundation of cell culture media development, optimization and feed strategies. Pre-Conference Workshop B: 20 May 2014 (1330-1700) Topics To Be Discussed Include: • Introduction to the Master Cell Bank (MCB) and Working Cell Bank (WCB) • Regulations surrounding cell banking • GMP cell banking • Ensuring the authenticity of cell banks • Analytical characterization procedures: Tests for identification, purity and stability • Best practices in contamination control • Bio-preservation methods: What are available and how to select the optimal method • Cell bank storage About Your Workshop Leaders: Sanjeev Gupta, Deputy General Manager – Biosimilars Development, IPCA Laboratories, India Dr Cheng Zhang, CSO/CTO, Gmax Biopharm, China Dr Cheng Zhang is the CSO/CTO of Gmax Biopharm, he has two decades of working experiences in the biomedical field including NIH and three biopharmaceutical companies (Hybridon, Millennium and Amgen) in the United States. He has multi-year working experiences in both small- molecule and antibody drug development, and is an experienced expert in therapeutic antibody discovery and development. The Road to Commercialization: From Cell to Market Post-Conference Workshop C: 23 May 2014 (0900-1700) Getting your innovative biologics into the competitive biopharmaceuticals market requires thorough planning and a good strategy to ensure commercial success. This workshop aims to introduce participants to the commercial aspects of R&D and how to ensure their product launch to market whether it is a launch of a new commercial cell line or new innovative biologic. Topics To Be Discussed Include: • Risks involved in cell line development • Cost-cutting measures that can be undertaken • What does it takes to launch a new commercial cell line into the market • Labour issues in hiring and retaining the right talents • Product pipelines strategies • Creating a business plan for a successful product launch Dr Zhongling Feng, CSO and Vice President, Viropro, USA Topics To Be Discussed Include: • Tips in designing and developing your ideal culture media that is best suited to your systems • Strategies to develop the cell culture media fast and efficiently • Determining the optimal conditions: Chemical and physiological conditions • What are the High throughput (HT) technologies available? • Case studies on how cell media affects cell culture results • Tips in selecting the right cell culture processes: Batch fed or perfusion • Approaches in designing feeding strategies for high yield and high quality products • Case studies on different feeding strategies About Your Workshop Leader: Dr. Zhongling Feng is Vice President and Chief Scientific Officer of Viropro, Inc. and has more than 15 years of experience in conducting basic and industrial research focused on discovering new therapies for globally important diseases. He received his M.D. and Ph.D. degree from China Medical University with residency training in radiation therapy. He completed post-doctoral training at Center for Biochemical and Biophysical Sciences and Medicine at Harvard Medical School and Department of Medicine at Brigham and Women's Hospital. He is an inventor on two patents, has 14 scientific publications and serves on the editorial board of World Journal of Stem Cells. Dr. Feng is currently responsible for leading the development and commercialization strategy to market approach for several biosimilars such as Rituximab and human biosimilar insulins at Viropro, Inc. In addition, he is leading to license many inventions and technologies for commercialization through external partnerships.

REGISTERTODAY! +6565082401/+862123263680 register@ibcasia.com.sg www.celllineasia.com BY INDUSTRY: ■ Pharmaceuticals/Biotechnology: 50% ■ Research Institutes/Universities: 10% ■ CMOs: 20% ■ CROs: 10% ■ Technology Providers: 10% BY REGION: ■ China, Taiwan, Hong Kong: 60% ■ Japan, Korea: 10% ■ Rest of Asia: 10% ■ Europe: 10% ■ USA: 5% ■ Australia: 5% Roche Diagnostics • Boehringer-Ingelheim • Genzyme • Sanofi • Shanghai Henlius Biotech • Eureka Therapeutics • Simcere • Luye Pharma • BTI A*Star • Neuclone •WuhanYZY biopharma •Wuxi apptec • Fountain Biopharma • Novo Nordisk • Harbin Pharmaceutical Group • Genor Biopharma •TTY Biopharm company • JS Biosciences • Hisun Medicine • Genloci Biotechnologies • Shanghai Jiaotong University • University of Queensland • University of Manchester • Swiss Institute of Technology • John Hopkins University School of Medicine • National Health Research Institutes • Autekbio • Genescience • Dragonfly Sciences • Eli Lilly and Company • Hengru Medicine • TPG Biologics • Sinocelltech • Jiangsu Henrui Medicine • Egret Pharma Shanghai • Beijing Mabworks Biotech • Cbiopharm • Japan Asia Inestment (China) • 3SBIO • Jiangsu T-Mab Biopharma • SG Austria • Lonza Biologics • Tap biosystems • Sigma-Alrich • Genscript China • GE Healthcare AND MANY MORE... Snapshot of Past Attending Companies Include: The global cell culture market is expected to reach USD 16.85 billion globally in 2018 (Transparency Market Research, 2013). However, the development of cell lines is still plagued with many challenges including quality, cost, timelines in the cell line development process, as well as titer. Due to the high cost of biologics production, strategies for cost-effective cell line development solutions to hasten the drug into the market can ultimately lead to high profit margins. IBC’s Cell Line Development & Engineering Asia brings together top experts and scientists from biopharma, biotechs, research institutes, universities, CMOs and CROs as well as leading technology solutions providers from all over Asia and the rest of the world. It provides a platform where industry and research experts can share research developments, case studies, best practices and discuss challenges pertaining to the cell line development industry to increase the efficacy and quality of cell lines for a faster, safer and more efficient biologics development process. The Biopharma Development & Production Week is the leading industry platform for pharma, biotech, CMOs, CROs, research institutes, investors and industry stakeholders to meet, network and discuss current industry trends, establish business partnerships and be updated on investment opportunities in China and surrounding Asia. Co-Located with: • Showcase the latest technology • Meet & Network with senior decision makers in Asia • Position your brand as the market leader to stand out amidst competition • Generate new business contacts and strengthen existing accounts LIMITED SPONSORSHIP & EXHIBITION OPPORTUNITIES AVAILABLE: Do you provide innovative technology to support cell line development in Asia? For sponsorship opportunities, contact Yvonne Leong at Tel: +65 6508 2489 Email: yvonne.leong@ibcasia.com.sg Who Should Attend: Abundant Networking Opportunities with Regional & Global Companies! BIOBIO MANUFACTURING BIOSIMILARSSIMILARSSIMILARSBIBI ASIA BI www.biosimilarsasia.com www.biomanufacturing-asia.com About the BDP Week Grow & Benchmark Your Company Profile in the Cell Line Industry Meet VIP Guests at Networking Luncheons Exchange Business Cards & Get to Know Your Peers in the Shared Morning Ice Breaker Speed Networking with Pharmaceutical & Biotechnology Companies Shared Networking Breaks & Exhibition Build Lasting Partnerships & Networks in a Casual Networking Evening Cocktail 20 — 23 May 2014 Grand Hyatt Shanghai, China Accelerating Your Cell Line Development with Efficacy & Quality Part of PRODUCTION BIOPHARMA DEVELOPMENT & WEEK C LL LINEC LL LINEC LL LINE DEVELOPMENT & ENGINEERING ASIA 3RD ANNUAL

GROUP BONUS: REGISTER 3 DELEGATES FROM THE SAME COMPANY AND THE 4TH ATTENDS FOR FREE! CREDIT CARD PAYMENTS The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at www.celllineasia.com and click “Register On-line”. If you would prefer to pay over the phone please complete the contact name and details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in the strictest confidence, please do not send payment details by email. Credit card contact: Department: Direct phone number: Email: Grand Hyatt Shanghai, China Jin Mao Tower, 88 Century Boulevard Pudong, Shanghai 200121 Tel: +86 21 5049 1234 | Fax: +86 21 5049 8381 Contact Person: Judy Xu Email: judy.xu@hyatt.com ENJOY SUBSTANTIAL SAVINGS WITH OUR MULTIPLE BOOKING DISCOUNT! Early Bird Rate Register & pay on or before 14 Mar 2014 FEE PER DELEGATE Special Rate Register & pay before 11 Apr 2014 Group Rate (3 or more delegates) Normal Rate Register & pay after 11 Apr 2014 111 Somerset Road, TripleOne Somerset #10-06, Singapore 238164 Tel: +65 6508 2400 Fax: +65 6508 2408 REGISTER NOW! FAX BACK TO +65 6508 2407 HOTEL INFORMATION DATA PROTECTION PAYMENT TERMS CANCELLATION / SUBSTITUTION IMPORTANT NOTE This label contains your priority booking code. To expedite registration, please do not remove label. If you have already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop. 6 EASY WAYS TO REGISTER REGNO.200108203N 3rd CELL LINE DEVELOPMENT & ENGINEERING ASIA RESERVE YOUR PLACE TODAY! P46237 USD 2,695 USD 2,895 USD 2,995 USD 2,495 If undelivered, please return to: MAIL the attached registration form with your cheque to IBC Asia (S) Pte Ltd c/o Informa Regional Business Services 111 Somerset Road, TripleOne Somerset #10-06, Singapore 238164 Email register@ibcasia.com.sg Fax +65 6508 2407 Web www.celllineasia.com SAVE WITH THE EARLY BIRD & SPECIAL RATES! Scan the QR Code with your smartphone and register today The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Occasionally, your details may be obtained from or shared with external companies who wish to communicate with you offers related to your business activities. If you do not wish your details to be used for this purpose, please contact our Database Department at Email: database@ibcasia.com.sg, Tel: +65 6508 2400 or Fax: +65 6508 2408. Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event. Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407). Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC assumes no further liability or obligation, beyond the refund of the paid registration fee, in the event of postponement or cancellation by IBC. ❑ Yes! I/We will attend the 3rd Cell Line Development & Engineering Asia 20 – 23 May 2014, Grand Hyatt Shanghai, China ❑ I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in. Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut-off date. All payments should be made in US or CNY dollars. • Payments by US$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” and mailed to: IBC Asia (S) Pte Ltd c/o Informa Regional Business Services 111 Somerset Road, TripleOne Somerset #10-06, Singapore 238164 Attn: The Accounts Receivable Team • Payment by telegraphic transfer in US$ must be made to: IBC Asia (S) Pte Ltd A/C No.: 260-457866-178 (USD) The Hongkong and Shanghai Banking Corporation Limited, 21 Collyer Quay, HSBC Building, Singapore 049320 Bank Swift Code: HSBCSGSG Bank Code: 7232 • Payment by telegraphic transfer in CNY must be made to: A/C Name: Conferences and Event Management Services (Shanghai) Co., Ltd. A/C No.: 720-031103-001 Beneficiary Bank: Bank (China) Company Limited Bank Address: No. 1000 Lujiazui Rind Road, Pudong, Shanghai 200120, P.R. China • Payment by credit card in US$ (AMEX, VISA or MasterCard) The best way to pay by credit card is through our secure portal built into the website. To pay by phone please indicate the contact name and details below and our Customer Services Team will call within 24 hours to take payment. Please do not send credit card information by email. HSBC IBC USD 2,495 USD 2,695 USD 2,795 USD 2,295 USD 2,295 USD 2,495 USD 2,595 USD 2,095 International Companies USD 1,995 USD 2,195 USD 2,295 USD 1,795 USD 1,695 USD 1,895 USD 1,995 USD 1,495 China Domestic Companies CNY 6,500 CNY 7,500 CNY 8,000 CNY 6,000 CNY 6,000 CNY 7,000 CNY 7,500 CNY 5,500 CNY 5,500 CNY 6,500 CNY 7,000 CNY 5,000 CNY 5,000 CNY 6,000 CNY 6,500 CNY 4,500 CNY 4,500 CNY 5,500 CNY 6,000 CNY 4,000 Who is Head of your Department? Who is Head of Training? Company Information Company Name: Address: Main Business/Activity: Postal Code: Please photocopy for additional delegates FREE GROUP DISCOUNT Delegate 1 Details Name: Dr/Mr/Ms Job Title: Department Tel: Mobile No.: Email: Delegate 2 Details Name: Dr/Mr/Ms Job Title: Department Tel: Mobile No.: Email: Delegate 3 Details Name: Dr/Mr/Ms Job Title: Department Tel: Mobile No.: Email: Delegate 4 Details Name: Dr/Mr/Ms Job Title: Department Tel: Mobile No.: Email: • Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time. Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate. • All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel. • Registration fees are subject to the prevailing government tax International companies have Global Headquarters located outside mainland China. A China domestic company has its global headquarters located within mainland China. Regulatory Authorities, Government and Academia will be accorded 40% off Normal Rates Payment Method (Please tick:) ❑ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd ❑ I am paying by bank transfer (copy attached) ❑ Payment by Credit Card. (AMEX, VISA or MasterCard accepted) Customer Service Hotline +65 6508 2401 [Singapore] +86 21 2326 3680 [China] ❑ 4 Days Package - 2 Day Conference + All Workshops (A+B+C) ❑ 3.5 Days Package - 2 Day Conference + Workshops (A or B + C) ❑ 3 Days Package - 2 Day Conference + Workshops (A+B or C) ❑ 2.5 Days Package - 2 Day Conference + Workshop (A or B) ❑ 2 Day Package - 2 Day Conference only ❑ 4 Days Package - 2 Day Conference + All Workshops (A+B+C) ❑ 3.5 Days Package - 2 Day Conference + Workshops (A or B + C) ❑ 3 Days Package - 2 Day Conference + Workshops (A+B or C) ❑ 2.5 Days Package - 2 Day Conference + Workshop (A or B) ❑ 2 Day Package - 2 Day Conference only

Add a comment

Related presentations

How organisms adapt and survive in different environment.

Aplicación de ANOVA de una vía, modelo efectos fijos, en el problema de una empres...

Teori pemetaan

Teori pemetaan

November 10, 2014

learning how to mapping

Libros: Dra. Elisa Bertha Velázquez Rodríguez

Materi pelatihan gis

Materi pelatihan gis

November 10, 2014

learning GIS

In this talk we describe how the Fourth Paradigm for Data-Intensive Research is pr...

Related pages

Home | 5th Annual Cell Line Development & Engineering ...

The conference will help you develop robust cell lines with maximum quality, productivity and efficiency for scalability in production. Glean effective ...
Read more

Speakers | 5th Annual Cell Line Development & Engineering ...

The conference will help you develop robust cell lines with maximum quality, productivity and efficiency for scalability in production. Glean effective ...
Read more

2nd Annual Cell Line Development and Engineering Asia

2nd Annual Cell Line Development and ... Development and Engineering Asia Conference ... Cell Line Development and Engineering Asia ...
Read more

Cell Line Development and Engineering Asia - 10times.com

Cell Line Development and Engineering Asia will be held in Shanghai, China starting on 16th May, 2016. This Conference is a 4 day event and will end on ...
Read more

6th Annual Cell Line Development & Engineering 2017 | IBC Asia

IBC Asia is a division of Informa plc, the largest publicly owned organiser of conferences and courses in the world providing inspiring marketplaces and ...
Read more

3rd annual Cell Line Development & Engineering Asia

3rd annual Cell Line Development & Engineering Asia Conference 20th to 23rd May 2014 Shanghai, China Website: http://www.celllineasia.com/ Contact person ...
Read more

Solentim sponsor 5th Annual Cell Line Development ...

Solentim sponsor 5th Annual Cell Line Development & Engineering Asia Conference in Shanghai Sponsoring, speaking and exhibiting. NEWS - Bournemouth, UK ...
Read more

Cell Line Development and Engineering

IBC Life Sciences' 12th annual Cell Line Development & Engineering is the leading forum to gather ... The conference will be ... Cell Line Development, ...
Read more

Informa Life Sciences - List of Events

Informa Life Sciences lead the market in providing quality, ... EuroPeptides 2015 Conference 15 ... Cell Line Development & Engineering.
Read more

Biopharma Development & Production Week Asia Pacific ...

The Biopharma Development & Production (BDP) Week Asia Pacific navigates through the ... Conference Day One 2 November ... Vice President and Head of Cell ...
Read more